Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases

The International Liver Tumor Group RAS-trial Radiofrequency Ablation Versus Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Randomized Trial

This randomized clinical phase III trial is testing the efficacy of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the treatment of colorectal carcinoma liver metastases.

Primary end point is local progression free survival.

Patients with 1-4 inoperable colorectal liver metastases, no more 4 cm in diameter are randomized to either RFA or SBRT. Primary end point i local progression free survival. Chemotherapy is allowed before and after study treatment.

Inclusion Criteria:

• Adenocarcinoma of the colon or rectum
• Liver metastases
• Inoperable (technical or medical)
• 1-4 metastases
• Maximum 40 mm in diameter
• Suitable for both therapies, RFA and SBRT

Exclusion Criteria:

• Uncontrolled extrahepatic disease and uncontrolled primary cancer
• Liver cirrhosis